Methods and compositions for determining, and for minimizing, the likelihood of development of allergy in infants

ABSTRACT

The invention relates to allergic disease, to the development of allergic disease in infants, to determining the likelihood of development of allergic disease in infants and to minimizing the likelihood of development of allergic disease in infants.

This application is a continuation of U.S. Pat. Application No.16/471,058 filed Jun. 19, 2019 which is a national phase applicationunder 35 U.S.C. § 371 of International Application No.PCT/AU2017/051453, filed Dec. 22, 2017, which claims the benefit ofAustralian Patent Application No. 2016905378, filed Dec. 23, 2016, theentirety of each referenced disclosure is incorporated herein byreference.

Pursuant to 37 C.F.R. 1.821(c), a sequence listing is submitted herewithas an ST.26 xml file named “SWIP.P0003US.C1 Sequence Listing.xml”,created on May 18, 2023 and having a size of 30 kilobytes. The contentof the aforementioned file is hereby incorporated by reference in itsentirety.

TECHNICAL FIELD OF THE INVENTION

The invention relates to allergic disease, to the development ofallergic disease in infants, to determining the likelihood ofdevelopment of allergic disease in infants and to minimizing thelikelihood of development of allergic disease in infants.

BACKGROUND OF THE INVENTION

Approximately 30% to 40% of the world’s population is affected byallergic disease and the prevalence is increasing. In Australia, forexample, there has been a 3-fold increase in emergency departmentpresentations due to food allergy anaphylaxis since the late 1990s,mostly explained by an increase among young children.

Evidence suggests that allergic disease may be associated withdiet-induced changes in the gut microbiome. Microbiota-accessiblecarbohydrates (MACs), found in plant derived dietary fiber, have beenproposed to play a role in shaping the gut microbial ecosystem, which,in turn, is believed to influence immune regulation. The gut microbiotaof hunter-gatherers that consume a high MAC diet contains greaterbacterial species diversity than the gut microbiota of Westerners. Inparticular, hunter-gatherers have a substantially greater abundance ofanaerobic organisms, mostly of the phyla Bacteroidetes, and inparticular the genus Prevotella. These anaerobic organisms have beenproposed to play a role in liberating energy from dietary MACs viafermentation resulting in the production of metabolites including shortchain fatty acids (SCFAs). SCFAs, in turn, are thought to increasemicrobial diversity, dampen inflammatory pathways, and promote thedevelopment of regulatory T cells (Treg) that are required to maintaintolerance to self and non-self antigens.

The majority of microbiome-immune research has focused on the postnatalperiod. There is however, evidence from mouse models that maternaldietary MAC intake during pregnancy induces changes in the maternal gutmicrobiome. In turn, maternal transfer of metabolites, including SCFAs,is thought to influence foetal immune programming and the development ofpostnatal allergic disease.

There remains a need to develop intervention strategies for minimizingthe likelihood of development of allergic disease in infants andchildren.

It will be understood that although a number of prior art publicationsare referred to herein such reference does not constitute an admissionthat any of these documents forms part of the common general knowledgein the art in any country.

SUMMARY OF THE INVENTION

The invention in a first aspect provides a method of determining whetheran offspring of a pregnant mother is susceptible to developing anallergic disease, the method comprising detecting the level of bacteriaof Prevotella 9 in a faecal sample from the pregnant mother, wherein theabsence of detectable Prevotella 9 or the presence of low levels ofPrevotella 9 indicates that the offspring is susceptible to developingan allergic disease.

A second aspect provides use of the method of the first aspect todetermine whether a pregnant mother should be treated to increase thelevel of bacteria of Prevotella 9 in their gut to reduce thesusceptibility of their offspring to developing an allergic disease.

A third aspect provides the use of the method of the first aspect todetermine whether a pregnant mother has been effectively treated toincrease the level of bacteria of Prevotella 9 in their gut.

A fourth aspect provides a method of preventing allergic disease in aninfant, the method comprising maintaining Prevotella 9 levels in theinfant’s mother when pregnant at a level of abundance that is (a)detectable, and (b) at higher levels of abundance.

The method of the fourth aspect may involve administering to theinfant’s mother a therapeutically effective amount of microbiotaaccessible carbohydrates, for example in the subject’s diet. The methodmay also comprises administering to the infant’s mother atherapeutically effective amount of a bacteria of the genus Prevotella9.

In an embodiment of each of the first to fourth aspects the allergicdisease is allergic rhinitis, IgE-mediated food allergy, atopicdermatitis, atopic wheeze and asthma.

A fifth aspect provides a kit for determining the level of bacteria ofPrevotella 9 in a sample, the kit comprising primers specific forPrevotella 9

The primers may be specific for Prevotella 9 X 16S ribosomal nucleicacid region of SEQ ID NO: 1:

TACGGAAGGTCCGGGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCGTGTTGTGAAATGTAGACGCTCAACGTCTGCACTGCAGCGCGAACTGGTTTCCTTGAGTACGCACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATCGAAC AGG (SEQ ID NO: 1)

In one embodiment the primers comprise: OTU_41 For

TACGGAAGGTCCGGGCGTTAT (SEQ ID NO: 3)

OTU_41Rev

AGTGCAGACGTTGAGCGTCTA (SEQ ID NO: 4)

The primers may be specific for target Prevotella 9 species Y 16Sribosomal nucleic acid region of SEQ ID NO: 2:

TACGTATGGTGCAAGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCGTGTTGTGAAATGTAGATGCTCAACATCTGAACTGCAGCGCGAACTGGTTTCCTTGAGTACGCACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATCGAAC AGG (SEQ ID NO: 2)

In one embodiment the primers comprise: OTU_697 For

TACGTATGGTGCAAGCGTT (SEQ ID NO: 5)

OTU_697 Rev

GCAGTTCAGATGTTGAGCATC (SEQ ID NO: 6)

Another aspect provides a method for minimizing the likelihood ofdevelopment of allergy in offspring or progeny of a female individualcomprising the step of administering Prevotella to the female individualthereby minimizing the likelihood of development of allergy in progenyof the female individual.

Another aspect provides a Prevotella for use by administration to afemale individual in minimizing the likelihood of development of allergyin progeny of the female individual.

Another aspect provides a use of Prevotella in a female individual tominimize the likelihood of development of allergy in progeny of thefemale individual.

Another aspect provides a composition formulated for human consumptioncomprising, or consisting of bacteria that is Prevotella.

Another aspect provides a composition formulated for human consumptioncomprising, or consisting of:

-   bacteria having a 16S rDNA sequence shown in SEQ ID No:1; or-   bacteria having a 16S rDNA sequence having at least 97% identity,    preferably 98% identity, preferably 99% identity with the sequence    shown in SEQ ID No:1 or-   bacteria having a 16S rDNA sequence shown in SEQ ID No: 2; or-   bacteria having a 16S rDNA sequence having at least 97% identity,    preferably 98% identity, preferably 99% identity with the sequence    shown in SEQ ID No:2.

Another aspect provides a composition comprising:

Prevotella copri, and a further ingredient that is beneficial for apregnant or lactating woman.

Another aspect provides a use of Prevotella in the manufacture of acomposition for administration to a female individual to minimize thelikelihood of development of allergy in progeny of the femaleindividual.

Further aspects and embodiments of the invention described in thepreceding paragraphs will become apparent from the followingdescription, given by way of example and with reference to theaccompanying figures.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows The National Centre for Biotechnology Information BLASTsimilarity search for OTU000041 in the 16S ribosomal RNA sequences(Bacteria and Archacea) indicates 100% homology with the speciesPrevotella copri strain 13464.

FIG. 2 shows the region of homology is in the V4 section of the gene(OTU000041 underlined).

FIG. 3 shows the distribution of the relative abundance of OTUscorresponding to the Prevotella genus among stool samples collectedduring pregnancy from mothers of infants with subsequent food allergyversus mothers of infants without food allergy.

FIG. 4 shows the distribution of the relative abundance of OTUscorresponding the taxa Prevotella_9 (OTU000041 and OTU000697) in stoolsamples collected during pregnancy from mothers of infants withsubsequent food allergy versus mothers of infants without food allergy.

FIG. 5 shows the distribution of the relative abundance of OTU000041(corresponding to the species Prevotella copri) in stool samplescollected in pregnancy among mothers of infants with subsequent foodallergy versus mothers of infants without food allergy.

FIG. 6 shows the distribution of the relative abundance of OTUscorresponding the taxa Prevotella_9 (OTU000041 and OTU000697) in stoolsamples collected during pregnancy from mothers of infants with atopicwheeze versus mothers of infants without atopic wheeze (controls).

FIG. 7 shows the distribution of the relative abundance of OTUscorresponding the taxa Prevotella_9 (OTU000041 and OTU000697) in stoolsamples collected during pregnancy from mothers of infants with atopiceczema versus mothers of infants without atopic eczema (controls).

FIG. 8 shows the distribution of the relative abundance of OTU000041(corresponding to the species Prevotella copri) in stool samplescollected in pregnancy among mothers of infants with subsequent atopiceczema versus mothers of infants without atopic eczema.

FIG. 9 shows the distribution of the relative abundance of OTU000041(corresponding to the species Prevotella copri) in stool samplescollected in pregnancy among mothers of infants with subsequent atopicwheeze versus mothers of infants without atopic wheeze.

FIG. 10 shows the distribution of the relative abundance of OTU000697 instool samples collected in pregnancy among mothers of infants withsubsequent food allergy versus mothers of infants without food allergy.

FIG. 11 shows the distribution of the relative abundance of OTU000697 instool samples collected in pregnancy among mothers of infants withsubsequent atopic wheeze versus mothers of infants without atopicwheeze.

FIG. 12 shows the distribution of the relative abundance of OTU000697 instool samples collected in pregnancy among mothers of infants withsubsequent atopic eczema versus mothers of infants without atopiceczema.

DETAILED DESCRIPTION OF THE INVENTION Standard Methods

Unless specifically defined otherwise, all technical and scientificterms used herein shall be taken to have the same meaning as commonlyunderstood by one of ordinary skill in the art (e.g., in microbiology,biochemistry, and immunology).

Unless otherwise indicated, the microbiology, biochemistry, andimmunological techniques utilized in the present invention are standardprocedures, well known to those skilled in the art. Such techniques aredescribed and explained throughout the literature in sources such as, J,Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons(1984), J. Sambrook and Russell., Molecular Cloning: A LaboratoryManual, 3^(rd) edn, Cold Spring Harbour Laboratory Press (2001), R.Scopes, Protein Purification - Principals and Practice, 3^(rd) edn,Springer (1994), T.A. Brown (editor), Essential Molecular Biology: APractical Approach, Volumes 1 and 2, IRL Press (1991), D.M. Glover andB.D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4,IRL Press (1995 and 1996), and F.M. Ausubel et al. (editors), CurrentProtocols in Molecular Biology, Greene Pub. Associates andWiley-Interscience (1988, including all updates until present), EdHarlow and David Lane (editors) Antibodies: A Laboratory Manual, ColdSpring Harbour Laboratory, (1988), and J.E. Coligan et al. (editors)Current Protocols in Immunology, John Wiley & Sons (including allupdates until present).

Definitions

In the present invention, the term “allergic disease” is a general termfor diseases in which allergic reaction is involved. More specifically,a disease which is an allergic disease is one associated with allergicsensitization. ‘Allergic sensitization’ refers to the production ofsignificant levels of allergen-specific IgE antibodies. Allergicsensitization can be identified by skin prick allergy testing or bymeasurement of serum allergen-specific IgE levels. Examples of allergensinclude food allergen, mite allergen, pollen allergen. Representativeallergic diseases include bronchial asthma, atopic wheeze, allergicrhinitis, atopic dermatitis, pollen allergy, food allergy, insectallergy, and such. Familial allergic diseases may also be called atopicdiseases.

“Allergen” as used herein refers to any naturally occurring protein ormixtures of proteins that may induce allergic reactions (i.e.IgE-mediated reactions, or allergic sensitization). Examples ofnaturally occurring allergens include pollen allergens (tree, weed, herband grass pollen allergens), mite allergens (from house dust mites andstorage mites), insect allergens (inhalant, saliva and venom originallergens), animal allergens (from saliva, hair and dander from dog,cat, horse, rat, mouse), fungi allergens and food allergens.

“Food allergy” as used herein refers to allergic sensitization and toIgE-mediated reaction to food allergens. Food sensitization may bedetected by a positive skin prick test (SPT) to a food allergen whichmay include cow’s milk, egg, peanut, sesame or cashew. A positive SPTmay be a wheal diameter at least 2 mm greater than that produced by anegative control solution, measured at 15 minutes. Food sensitizationmay also be detected by the presence of elevated levels of allergenspecific IgE in serum.

“Atopic wheeze” as used herein refers to the presence of parent-reportedwheeze during the first year of life associated with allergicsensitization. Atopic wheeze may be assessed by SPT wherein a positiveSPT result and wheeze indicates atopic wheeze. The SPT may measuresensitization to any of the food antigens or other allergens oraeroallergens herein.

“Atopic eczema” as used herein refers to the presence of eczema asdefined according to the Modified UK working party criteria for infantsunder 12 months (Williams, Burney et al. 1994, Fleming, Bodner et al.2001). Atopic eczema may be assessed by SPT wherein a positive SPTresult and eczema indicates atopic eczema. The SPT may measuresensitization to any of the food antigens or other allergens oraeroallergens herein.

“Microbiota” as used herein refers to one or more bacterial communitiesthat can be found or can exist (colonize) within a gastrointestinaltract of a host organism, also described herein as “gut microbes”.

“Operational taxonomic units” (OTUs) as used herein refers to groups oforganisms grouped by DNA sequence similarity.

“Microbiota-accessible carbohydrates” (MACs)as used herein refers tocarbohydrates that are resistant to digestion by a host’s metabolism,and are made available for gut microbes, as prebiotics, to consume orferment or metabolize or convert into beneficial compounds or substancesor metabolites, such as short chain fatty acids. Microbiota accessiblecarbohydrates as used herein are particularly found in “high fiber”diets and have the effect of increasing the level of certain species ofbacteria in the gut.

“Prebiotic” as used herein refers to any substance that can be consumedby a relevant bacteria, or that otherwise assists in keeping therelevant bacteria alive or stimulates its growth.

“Short chain fatty acids” as used herein refers to fatty acids withfewer than six carbon atoms and include, but are not limited to,acetate, butyrate and propionate.

“Gut” as used herein refers to the digestive tract, in particular theintestine and stomach. An “increase in the gut” as used herein refers toan increase in the level of bacteria present in a feacal sample, asbeing indicative of gut levels.

“Offspring” as used herein refers to one or more immediate children oryoung or progeny of a particular pregnant female from a singlepregnancy.

A “subject” as used herein may be human or a non-human animal, forexample a domestic, a zoo, or a companion animal. In one embodiment, thesubject is a mammal. The mammal may be an ungulate and/or may be equine,bovine, ovine, canine, or feline, for example. Accordingly, the presentinvention has human medical application, and also veterinary and animalhusbandry applications, including treatment of domestic animals such ashorses, cattle and sheep, and companion animals such as dogs and cats.

An infant subject is a subject less than 1 year of age.

“Prevotella” as used herein refers to a genus of gram negative anaerobicbacteria of the phylum Bacteroidetes. OTUs 41 and 697 as having the bestsupport (p-values adjusted for multiple testing 0.003 and 0.009respectively; next lowest p-value 0.19) were classified as Prevotella_9,a subgroup of Prevotella containing two described species, Prevotellacopri and P. paludivivens. Prevotella 9 species X as used herein refersto a strain of Prevotella identifiable by 97% sequence identity tooperational taxonomic unit (OTU) 000041 at the V4 16S rDNA locus, whichin turn has 100% sequence identity to Prevotella copri. Prevotella 9species Y as used herein refers to a Prevotella species identifiable by97% sequence identity to OTU 000697 at the V4 16S rDNA locus. This has98% similarity to P. copri but is likely a separate strain or specieswithin Prevotella. Prevotella species X and Prevotella species Y areboth classified into the Prevotella 9 subgroup.

A composition “conditioned by” Prevotella as used herein refers tocomposition that comprises secretions of Prevotella. The composition ispreferably acellular. Such a composition may be the supernatant of aculture of Prevotella from which bacterial cells and fragments have beenremoved.

A composition of the invention that is “formulated for humanconsumption” as used herein refers to a composition that (a) containsexcipients, diluents or carriers that are generally regarded as safe forconsumption by humans and/or (b) does not contain ingredients orcomponents that are unsafe for human consumption.

Throughout the description and claims of this specification, the word“comprise” and variations of the word, such as “comprising” and“comprises”, means “including but not limited to”, and is not intendedto exclude other additives, components integers or steps.

“Nucleic acid” as used herein refers to DNA molecules (e.g. cDNA orgenomic DNA), RNA molecules (e.g. mRNA), DNA-RNA hybrids, and analogs ofthe DNA or RNA generated using nucleotide analogs. The nucleic acidmolecule can be a nucleotide, oligonucleotide, double-stranded DNA,single-stranded DNA, multi-stranded DNA, complementary DNA, genomic DNA,non-coding DNA, messenger RNA (mRNA), microRNA (miRNA), small nucleolarRNA (snoRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), smallinterfering RNA (siRNA), heterogeneous nuclear RNAs (hnRNA), or smallhairpin RNA (shRNA).

The term “therapeutically effective amount” refers to an amount ofmicrobiota accessible carbohydrate or bacteria of Prevotella 9 capableof treating allergic disease in a subject or preventing allergic diseasein the offspring of a subject receiving the treatment.

The terms “treat”, “treating” or “treatment” refer to both therapeutictreatment and prophylactic or preventative measures, wherein the aim isto prevent or ameliorate allergic disease in an infant subject or slowdown (lessen) progression of allergic disease in an infant subject.Infant subjects in need of treatment include those already with theallergic disease as well as those in which development of the allergicdisease is to be prevented by treatment of the mother in pregnancy orthe infant.

“Conditioning” with respect to the female individual generally refers tobringing the female individual to a desired state in which thelikelihood of development of allergic disease in progeny of the femaleindividual is minimized or reduced. This may generally be achievedaccording to the methods described herein.

As used herein, the phrase “level of bacteria” refers to the number,concentration or amount of bacteria in a sample and the phrase“increasing the level of a bacteria” refers to an increase in thenumber, concentration or amount of a bacterium or bacterial DNA in thesample as a result of treatment as described herein, and when comparedto a subject who has not been treated according to the method describedherein.

As used herein the “level of bacteria” is a “marker” or “biomarker”indicative or predictive of allergic disease. A “marker” or “biomarker”refers to a biochemical, genetic, metabolic or molecular characteristicor substance or metabolite that is indicative or predictive of allergicdisease. As such, the “level of a biomarker or marker” may be indicativeof the “level of bacteria”.

A level of bacteria in a sample below a “reference level”, as usedherein, is predictive of allergic disease. For Prevotella 9 species X,the “reference level” of bacteria is the presence of detectable DNAspecific to species X in the faecal sample. For Prevotella 9 species Y,the “reference level” of bacteria is the presence of detectable DNAspecific to species Y in the faecal sample. Our data further indicatethat among mothers with detectable Prevotella 9 species X and/orPrevotella 9 species Y a relative abundance of this OTU relative to thetotal OTU count in the sample greater than 0.0003 is associated with agreater decrease in offspring allergic disease.

As used herein, “determining whether an offspring of a pregnant motheris susceptible to developing an allergic disease” “ refers to detectingor diagnosing allergic disease in an infant subject, or predicting orprognosing, that an infant subject is likely to develop allergic diseaseby assaying the infant’s mother during pregnancy. The invention alsoencompasses detecting susceptibility to allergic disease in an infantsubject. “Susceptible” as used herein is defined as detecting a level ofbacteria of the genus Prevotella 9 species X and/or Y below thereference level. Further that detectable but low abundance of Prevotella9 species X and/or Y is associated with greater offspring allergicdisease than greater abundance of detectable Prevotella species X and/orY.

“Maintaining Prevotella 9 species X and/or Y levels in the infant’smother when pregnant at above reference level” as used herein refers tomaintaining Prevotella 9 species X levels within a detectable range in afaecal sample from the mother, and maintaining Prevotella 9 species Ylevels within a detectable range. Further, that maintaining higherlevels of Prevotella species X and/or Y levels in the infant’s motherwhen pregnant is associated with a greater decrease in offspringallergic disease. Repeated testing could be used to encourageoptimization of (a) the level of bacteria of Prevotella 9 present duringpregnancy, and (b) the duration of pregnancy during which Prevotella 9species are present during pregnancy.

A. Determining Likelihood of Development of Allergic Disease in Infants

The invention in a first aspect provides a method of determining whetheran offspring of a pregnant mother is susceptible to developing anallergic disease, the method comprising detecting the level of bacteriaof Prevotella 9 in a faecal sample from the pregnant mother, wherein theabsence of detectable Prevotella 9 or the presence of low levels ofPrevotella 9 indicates that the offspring is susceptible to developingan allergic disease.

The invention provides a method for determining the likelihood of afemale individual forming offspring having allergic disease. The methodcomprises the following steps:

-   -providing a control describing the relative abundance of Prevotella    16S rDNA in the stool of a mother who has offspring who do not have    allergic disease;-   obtaining a sample from the female individual for whom the    likelihood of forming offspring having allergic disease is to be    determined, thereby forming a test sample;-   comparing the test sample with the control to assess whether the    test sample has a relative abundance of Prevotella 16S rDNA as    described in the control;-   determining that the female individual has a low likelihood of    forming offspring having allergic disease where the test sample has    a relative abundance of Prevotella 16S rDNA as described in the    control-   determining that the female individual has a high likelihood of    forming offspring having allergic disease where the test sample has    a relative abundance of Prevotella 16S rDNA that is not described in    the control.

A female individual having a lower relative abundance of a Prevotella16S rDNA, especially of OTU00041 or SEQ ID No: 1 than the control has ahigher likelihood of forming offspring having allergic disease.

A female individual having no OTU000697 or SEQ ID No:2, or lowerrelative abundance of OTU000697 or SEQ ID No:2 than the control, has ahigher likelihood of forming offspring having allergic disease.

The control may be derived from one mother, preferably from a cohort ofmothers, at least about 10, 20, 50 or 100 mothers.

The control may be in the form of a data file, or in the form of abiological sample.

The control or test sample may be based on assessment of a stool sample,or on the basis of a biological sample from which the amount of 16S rDNAin the stool can be determined. Preferably the test sample is based onassessment of a stool.

The relative abundance of 16S rDNA may be determined by any of thetechniques described below under this sub-heading. The technique maymeasure the amount of 16S rDNA directly, or indirectly by measuring someother parameter, for example cfu of Prevotella isolated from a sample.

The method may comprise the assessment of relative abundance of 16Sribosomal nucleic acid of Prevotella­_9, or Prevotella_9 species X, orPrevotella_9 species Y, or OTU00041 or OTU00697, or of SEQ ID No: 1 orof SEQ ID No: 2.

The control may describe the relative abundance of OTU00041 or SEQ IDNo: 1, or OTU000697 or SEQ ID No: 2. The test sample may be assessed todetermine relative abundance of OTU00041 or SEQ ID No: 1, or OTU000697or SEQ ID No: 2.

The method may utilize an oligonucleotide having a sequence shown in SEQID No: 3, 4, 5 or 6.

The female individual for whom the likelihood of forming offspringhaving allergic disease is to be determined may be pregnant, or planningpregnancy. Preferably the female individual is pregnant.

Methods for determining the level or amount of bacteria in a sample areknown to those skilled in the art. The presence of bacteria may beidentified using microbiological culture techniques, biochemical assaysor molecular techniques including, but not limited to, PCR (polymerasechain reaction), nucleic acid hybridisation or sequencing techniques.Alternatively, the method may comprise amplifying a bacterial nucleicacid sequence by a technique such as PCR and cloning and/or sequencingthe nucleic acid. Identification of bacteria may also be achieved bysequencing of 16S rDNA, including the use of next-generationhigh-throughput sequencing technologies.

Bacteria may also be detected using immunological methods. For example,antisera or antibodies cross reactive with a bacteria of the genusPrevotella 9 species X and/or Y may be used in a suitable immunologicalassay. Immunogical assays include enzyme-linked immunosorbent assay(ELISA), and those that use solid supports such as dip-stick typeassays. Such immunological assays may utilise labelled antibodies,including fluorescent, radioactive or chemiluminescent labelledantibodies or dye molecules.

Any suitable technique that allows for the qualitative and/orquantitative detection of a nucleic acid from a bacteria of the genusPrevotella 9 species X and/or Y may be used. Comparison may be made byreference to a standard control, or to a negative control. The nucleicacid may be labelled and hybridised on a gene array, in which case thegene concentration will be directly proportional to the intensity of theradioactive or fluorescent signal generated in the array.

In certain embodiments of the present invention, ribosomal nucleic acidcan be used to distinguish and detect bacteria. For example, bacterialribosomes are comprised of a small and large subunit, each which isfurther comprised of ribosomal nucleic acid and proteins. A large numberof ribosomal nucleic acids have been sequenced, and these are publiclyavailable in various accessible databases. Thus, in one embodiment,bacteria of the genus Prevotella 9 species X and/or Y is detected in asample by sequencing 16S ribosomal nucleic acid amplicons generated bydomain-level PCR reactions amplifying from genomic DNA. Traditionally,sequencing of ribosomal nucleic acids was performed by cloning andSanger (capillary electrophoresis) sequencing of PCR amplicons. Theadvent of next-generation sequencing has simplified and increased thesequencing depth for 16S ribosomal nucleic acid sequencing.

Accordingly, a “nucleic-acid-based detection assay” as used herein, isan assay for the detection of a target sequence within a target nucleicacid and utilizing one more oligonucleotides that specifically hybridizeto the target sequence.

B. Minimizing the Likelihood of Development of Allergic Disease

A fourth aspect provides a method of preventing allergic disease in aninfant, the method comprising maintaining Prevotella 9 levels in theinfant’s mother when pregnant at a level of abundance that is (a)detectable, and (b) at higher levels of abundance.

The invention provides a method for conditioning a female individual tominimize the likelihood of development of allergy in offspring orprogeny of the female individual. It will be understood that theadministration of Prevotella to the female individual is for the purposeof conditioning the female individual, or in other words, for thepurpose of preparing the female so as to minimize the likelihood thatthe female might form offspring or progeny having allergy. Relevantly,the administration of Prevotella is not a therapeutic use of Prevotellabecause it is not for the purpose of treating a disease or condition orailment of the female.

The invention provides a method for minimizing the likelihood ofdevelopment of allergy in offspring or progeny of a female individual.

The methods of the invention comprise the step of administeringPrevotella to the female individual. The administration of Prevotella tothe female individual is to minimize the likelihood of development ofallergy in progeny of the female individual. As exemplified herein, theabsence of maternal carriage of Prevotella is strongly associated with ahigher likelihood of development of allergic disease in offspring. Itfollows that this risk factor is minimised by the administration ofPrevotella to the female individual.

The invention provides Prevotella for use by administration to a femaleindividual in minimizing the likelihood of development of allergy inprogeny of the female individual.

The invention provides a use of Prevotella in a female individual tominimize the likelihood of development of allergy in progeny of thefemale individual.

The female individual may be an individual who has been assessed todetermine the likelihood of development of allergic disease in herprogeny including according to a method under the previous subheading.On the basis of the assessment, the female individual is administeredPrevotella. The female individual may be administered Prevotellairrespective of the assessment outcome.

Where the female individual is assessed to determine her likelihood offorming progeny having allergy, it is preferred that the assessment is aconsideration of her carriage of Prevotella. The assessment may be todetermine whether the female individual has an absence of detectablePrevotella in her gut. Alternatively, the assessment may be to determinethe relative abundance of Prevotella in her gut. Preferably theassessment is to determine whether the female individual has an absenceof detectable Prevotella in her gut. The assessment may be on the basisof detection of Prevotella specific polynucleotide sequences in her gutor faeces, for example utilizing nucleic acid detection techniquesdescribed herein. In other embodiments, the assessment of the riskfactor may be generally on the basis of a consideration discussed above.

In another embodiment, the female individual to whom the method isapplied has not been assessed to determine the likelihood of formingprogeny having allergic disease. According to this embodiment, thefemale individual is unaware of her risk profile for forming progenyhaving allergic disease. According to the embodiment, the femaleindividual is administered Prevotella simply to minimize the risk thatwould apply should she have a high likelihood of forming progeny havingallergic disease.

The female individual may be a prospective mother (i.e. a female who isyet to fall pregnant and who intends to do so) or an expectant mother(i.e. a pregnant female).

In one embodiment, the female individual is an expectant mother i.e.pregnant when the first administration of Prevotella is given to thefemale individual.

In another embodiment, the female individual is not pregnant (i.e may bea prospective mother) at the time of first administration of Prevotella.For example, Prevotella may be given to a prospective mother 1 to 3months, preferably no more than about 6 months to a prospective motherprior to her falling pregnant. In this embodiment, Prevotella may alsobe administered to the female individual during pregnancy.

The Prevotella may be administered in the 1^(st), 2^(nd) or 3^(rd)trimester, or in all trimesters. In one embodiment, the Prevotella isadministered in the 3^(rd) trimester only. In one embodiment, thePrevotella is administered in the 2^(nd) trimester only. In oneembodiment, the Prevotella is administered in the 2^(nd) and 3^(rd)trimester only. In one embodiment, the Prevotella is admininstered forat least 2 months, more preferably for at least 4 months beforedelivery. Thus the female individual may receive Prevotella for part orall of her pregnancy.

In one embodiment, the female individual herself may be at risk ofatopic disease. For example, a prospective mother, or expectant mothermay have atopic sensitization and either a history of allergic diseaseor active allergic disease. Examples include atopic eczema, allergicrhinoconjunctivitis, food allergy or asthma. As mentioned above, theadministration of Prevotella is not for the purpose of treating adisease or condition or ailment of the female.

In the above described embodiments, the Prevotella that is administeredto the female individual may comprise, or may consist of Prevotella_9.The Prevotella that is administered to the female individual maycomprise, or may consist of Prevotella_9 species X. The Prevotella thatis administered to the female individual may comprise, or may consist ofPrevotella_9 species Y. The Prevotella that is administered to thefemale individual may comprise, or may consist of Prevotella copri. ThePrevotella that is administered to the female individual may comprise,or may consist of bacteria having a 16S rDNA sequence shown in SEQ IDNo:1; or bacteria having a 16S rDNA sequence having at least 97%identity, preferably 98% identity, preferably 99% identity with thesequence shown in SEQ ID No:1 or bacteria having a 16S rDNA sequenceshown in SEQ ID No: 2; or bacteria having a 16S rDNA sequence having atleast 97% identity, preferably 98% identity, preferably 99% identitywith the sequence shown in SEQ ID No:2.

In the above described embodiments, the female individual may beadministered with Prevotella to provide from 1×10⁶ to 1×10¹¹ colonyforming units (cfu) of Prevotella per day to the female individual.

The Prevotella may be administered once or twice daily, for example atmeal times, or once every 2 or 3 days, or once weekly.

In the above described embodiments, the Prevotella may be provided inthe form of a composition. Compositions are described under thefollowing sub-heading.

Typically, Prevotella is provided orally to the female individual in theform of a capsule, tablet or like formulation adapted for oraladministration. In another embodiment the Prevotella may be provided inthe form of a food or beverage. Prevotella can be administered to theprospective or expectant mother in a variety of ways as long as it thereis contact between the Prevotella and the gastro-intestinal tract of themother, preferably with about 10⁷ to 10¹¹ bacteria.

The invention provides a method for conditioning a pregnant female tominimize the likelihood of her forming progeny that will developallergic disease, or otherwise, to minimize the likelihood ofdevelopment of allergy in progeny of the pregnant female, comprisingorally administering a composition comprising Prevotella copri, to thepregnant female, wherein the administration provides the pregnant femalewith about 10⁶ to 10¹¹ cfu per day throughout the 3^(rd) trimester,thereby minimizing the likelihood of her forming progeny that willdevelop allergic disease.

The invention provides a composition comprising Prevotella copri for useby oral administration to a pregnant female to provide the pregnantfemale with about 10⁶ to 10¹¹ cfu per day throughout the 3^(rd)trimester, in minimizing the likelihood of development of allergy inprogeny of the female individual.

The invention provides a use of Prevotella copri in the manufacture of acomposition for oral administration to a pregnant female to provide thepregnant female with about 10⁶ to 10¹¹ cfu per day throughout the 3^(rd)trimester, to minimize the likelihood of development of allergy inprogeny of the female individual.

C. Compositions

The invention provides a composition formulated for human consumption.Typically the composition does not comprise supernatant from Prevotellaculture, or components of culture media for culture of Prevotella, otherthan water. The composition may be used in an above described method tominimize the likelihood of development of allergy in offspring. In oneembodiment, the composition formulated for human consumption maycomprise, or consist of bacteria that is Prevotella. The compositionformulated for human consumption may comprise, or consist of bacteriathat is Prevotella_9. The composition formulated for human consumptionmay comprise, or consist of bacteria that is Prevotella_9 species X. Thecomposition formulated for human consumption may comprise, or consist ofbacteria that is Prevotella_9 species Y. The composition formulated forhuman consumption may comprise, or consist of bacteria that isPrevotella copri. In the aforementioned embodiments, the composition mayfurther include a further ingredient selected from the group consistingof a vitamin, a mineral, a long chain polyunsaturated fatty acid, a nondigestible oligosaccharide, or a protein, fat or digestiblecarbohydrate.

In another embodiment there is provided a composition formulated forhuman consumption. Typically the composition does not comprisesupernatant from bacterial culture, or components of culture media forculture of bacteria, other than water. The composition may be used in anabove described method to minimize the likelihood of development ofallergy in offspring. In one embodiment, the composition formulated forhuman consumption may comprise, or consist of, bacteria selected fromthe group consisting of: bacteria having a 16S rDNA sequence shown inSEQ ID No: 1; or bacteria having a 16S rDNA sequence having at least 97%identity, preferably 98% identity, preferably 99% identity with thesequence shown in SEQ ID No:1 or bacteria having a 16S rDNA sequenceshown in SEQ ID No: 2; or bacteria having a 16S rDNA sequence having atleast 97% identity, preferably 98% identity, preferably 99% identitywith the sequence shown in SEQ ID No:2. In the aforementionedembodiments, SEQ ID No: 1 or SEQ ID No: 2 may each form a V4 structureof a ribosomal RNA molecule. In the aforementioned embodiments, thecomposition may further include a further ingredient selected from thegroup consisting of a vitamin, a mineral, a long chain polyunsaturatedfatty acid, a non-digestible oligosaccharide, or a protein, fat ordigestible carbohydrate.

In another embodiment there is provided a composition formulated forhuman consumption. Typically the composition does not comprisesupernatant from Prevotella culture, or components of culture media forculture of Prevotella, other than water. The composition may be used inan above described method to minimize the likelihood of development ofallergy in offspring. In one embodiment, the composition formulated forhuman consumption may comprise, or consist of, bacteria selected fromthe group consisting of: bacteria having a 16S rDNA sequence shown inSEQ ID No:8; or bacteria having a 16S rDNA sequence having at least 80%identity to the sequence shown in SEQ ID No: 8, provided that thesequence includes V4 16S rDNA sequence shown in SEQ ID No: 7; orbacteria having a 16S rDNA sequence shown in SEQ ID No:9; or bacteriahaving a 16S rDNA sequence having at least 80% identity to the sequenceshown in SEQ ID No: 9, provided that the sequence includes V4 16S rDNAsequence shown in SEQ ID No: 7; or bacteria having a 16S rDNA sequenceshown in SEQ ID No: 10; or bacteria having a 16S rDNA sequence having atleast 80% identity to the sequence shown in SEQ ID No: 10, provided thatthe sequence includes V4 16S rDNA sequence shown in SEQ ID No: 7; orbacteria having a 16S rDNA sequence shown in SEQ ID No: 11; or bacteriahaving a 16S rDNA sequence having at least 80% identity to the sequenceshown in SEQ ID No: 11, provided that the sequence includes V4 16S rDNAsequence shown in SEQ ID No: 7; or bacteria having a 16S rDNA sequenceshown in SEQ ID No: 12; or bacteria having a 16S rDNA sequence having atleast 80% identity to the sequence shown in SEQ ID No: 12, provided thatthe sequence includes V4 16S rDNA sequence shown in SEQ ID No: 7. In theaforementioned embodiments, bacteria may be a strain having a 16S rDNAsequence having at least 85%, or 90%, or 95%, or 96%, or 97%, or 98%, or99% identity to the sequence shown in any one of SEQ ID No: 8, 9, 10,11, or 12, provided that the sequence includes SEQ ID No: 7. In theaforementioned embodiments, the composition may further include afurther ingredient selected from the group consisting of a vitamin, amineral, a long chain polyunsaturated fatty acid, a non digestibleoligosaccharide, or a protein, fat or digestible carbohydrate.

In another embodiment there is provided a composition formulated forhuman consumption comprising a strain of Prevotella copri that has beenisolated from anaerobic culture medium supernatant, the strain having a16S rDNA sequence having at least 50% identity to the sequence shown inSEQ ID No: 8 provided that the sequence includes SEQ ID No: 7.

In the above described compositions, bacteria may be a strain having a16S rDNA sequence having at least 85%, or 90%, or 95%, or 96%, or 97%,or 98%, or 99% identity to the sequence shown in any one of SEQ ID No:8, 9, 10, 11, or 12, provided that the sequence includes SEQ ID No: 7.

In the above described embodiments, the composition may further includea further ingredient selected from the group consisting of a vitamin, amineral, a long chain polyunsaturated fatty acid, a non digestibleoligosaccharide, or a protein, fat or digestible carbohydrate.

Percent sequence identity may be determined by conventional methods, bymeans of computer programs known in the art such as GAP provided in theGCG program package (Program Manual for the Wisconsin Package, Version8, August 1994, Genetics Computer Group, 575 Science Drive, Madison,Wisconsin, USA 53711) as disclosed in Needleman, S. B. and Wunsch, CD.,(1970), Journal of Molecular Biology, 48, 443-453, which is herebyincorporated by reference in its entirety. GAP may be used with thefollowing settings for polynucleotide sequence comparison: GAP creationpenalty of 5.0 and GAP extension penalty of 0.3.

In another embodiment there is provided a composition formulated forhuman consumption comprising a strain of bacteria deposited as DSMnumber 18205 (JCM13464; CB7) with Leibniz Institute DSMZ-GermanCollection of Microorganisms and Cell Cultures, Inhoffenstraβe 7B 38124Braunschweig GERMANY. The composition may further include a furtheringredient selected from the group consisting of a vitamin, a mineral, along chain polyunsaturated fatty acid, a non digestible oligosaccharide,or a protein, fat or digestible carbohydrate.

In embodiments herein, reference to a bacterial strain specified by DSMnumber 18205 may be taken to encompass variants thereof having at least80% identity with the 16S rRNA sequence of said specified strain,preferably at least 85% identity, more preferably at least 90% identity,further preferably at least 95% identity. In a particularly preferredembodiment, said variant has at least 97% identity with the 16S rRNAsequence of said specified strain, more preferably at least 98%identity, more preferably at least 99% identity.

In embodiments herein reference to Prevotella copri or DSM number 18205may be taken to include functionally equivalent bacteria derivedtherefrom such as but not limited to mutants, variants or geneticallytransformed bacteria. These mutants or genetically transformed strainscan be strains wherein one or more endogenous gene(s) of the parentstrain has (have) been mutated, for instance to modify some of theirmetabolic properties (e.g., their ability to ferment sugars, theirresistance to acidity, their survival to transport in thegastrointestinal tract, their post-acidification properties or theirmetabolite production). They can also be strains resulting from thegenetic transformation of the parent strain to add one or more gene(s)of interest, for instance in order to give to said geneticallytransformed strains additional physiological features, or to allow themto express proteins of therapeutic or prophylactic interest that onewishes to administer through said strains. These mutants or geneticallytransformed strains can be obtained from the parent strain by means ofconventional techniques for random or site-directed mutagenesis andgenetic transformation of bacteria, or by means of the technique knownas “genome shuffling”.

In one embodiment there is provided a composition comprising:

-   Prevotella copri; and-   a further ingredient that is beneficial for a pregnant or lactating    woman.

The further ingredient may be a micronutrient. The micronutrient may bea vitamin selected from the group consisting of: vitamin B1 (thiamine),vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B5 (pantothenicacid), vitamin B6 (pyridoxine), folic acid, vitamin B12(cyanocobalamine), biotin, choline, and vitamin C, vitamin D3, vitamin Eand vitamin K.

The micronutrient may be a mineral selected from the group consisting ofcalcium, phosphorus, zinc, iodine, iron, manganese, selenium, copper,and magnesium.

The micronutrient may be a long chain polyunsaturated fatty acid(LC-PUFA). The LC-PUFA may be selected from fatty acids having fattyacyl chain with a length of 20 carbon atoms or more and at least twounsaturated bonds. The LC-PUFA may be selected from the group consistingof eicosapentaenoic acids and/or acyl chain (EPA), docosahexaenoic acidand/or acyl chain (DHA) and arachidonic acid and/or acyl chain (AA).

The composition may further include a further bacteria species. Thefurther bacteria species may be selected to (i) reduce the likelihood offood allergy in neonates or infants; and/or (ii) reduce likelihood ofinflammation of breast tissue. The further bacteria species may be ofgenus Lactobacillus or Bifidobacterium. The further bacteria species maybe selected from the group consisting of the Lactobacillus accidophilusgroup, L. rhamnosus, L. casei, L. paracasei, L. plantarum, L. reuteri,L. fermentum, Bifidobacterium infantis, B. animalis subsp. lactis, B.breve, B. longum and B. bifidum.

The composition may further include a non-digestible oligosaccharide.The non-digestible oligosaccharide may be selected from the groupconsisting of: fructo-oligosaccharides (such as inulin),galacto-oligosaccharides (such as transgalacto-oligosaccharides orbeta-galacto-oligisaccharides), gluco-oligosaccharides (such as gentio-,nigero- and cyclodextrin-oligosaccharides), arabino-oligosaccharides,mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides,arabinogalacto-oligosaccharides, glucomanno-oligosaccharides,galactomanno-oligosaccharides, sialic acid oligosaccharides and uronicacid oligosaccharides.

The composition may further include a macronutrient. The macronutrientmay be selected from the group consisting of: protein, fat anddigestible carbohydrate.

The Prevotella -containing composition may comprise dead bacteria, orlive bacteria or a mixture of dead and live bacteria. Preferably atleast some of the Prevotella comprised in the composition are livingbacteria. Where provided in the form of a unit dose composition (such asa tablet or capsule) a unit dose may have from about 1×10⁶ to 1×10¹² cfuof Prevotella. In other embodiments, a single dosage unit may provideless than 1×10⁶ to 1×10¹² cfu of Prevotella, in which case, 2 or moredosage units are required to provide 1×10⁶ to 1×10¹² cfu of Prevotella.

In one embodiment there is provided a composition conditioned by abacteria described above, preferably by Prevotella copri bacteria or bya bacteria having a 16S rDNA sequence shown in SEQ ID No:1; or by abacteria having a 16S rDNA sequence having at least 97% identity,preferably 98% identity, preferably 99% identity with the sequence shownin SEQ ID No:1, or by a bacteria having a 16S rDNA sequence shown in SEQID No: 2, or by a bacteria having a 16S rDNA sequence having at least97% identity, preferably 98% identity, preferably 99% identity with thesequence shown in SEQ ID No:2. The composition may be used in the abovedescribed method for minimizing the likelihood of development of allergyin offspring. In one embodiment the composition is acellular. Thecomposition may further comprise a further ingredient that is beneficialfor a pregnant or lactating woman selected from the group consisting ofa mineral, a vitamin, a long chain polyunsaturated fatty acid, anon-digestible oligosaccharide, or a macronutrient selected from adigestible carbohydrate, a fat or oil and protein.

In the above described embodiments, the composition may be provided inthe form of a capsule, tablet, bead or powder or in the form of a foodproduct.

In the above described embodiments where the composition comprisesPrevotella, especially Prevotella copri, the Prevotella cells may bedried, may be microencapsulated, may be coated with an enteric coating(as described below), having an enteric coating.

In the above described embodiments where the composition comprisesPrevotella, especially Prevotella copri, may be provided in a formenabling re-hydration before administration.

In one embodiment, the composition may further comprise a desiccant.

In one embodiment, the composition may further comprise anosmoprotectant.

In one embodiment, the composition may further comprise acryoprotectant.

E. Manufacture

The invention provides a use of Prevotella in the manufacture of acomposition for administration to a female individual to minimize thelikelihood of development of allergy in progeny of the femaleindividual.

Prevotella copri may be produced by culture of a strain of bacteriadeposited as DSM number 18205 described above.

Alternatively, Prevotella copri may be isolated from feces and theisolate used to produce Prevotella copri cells in culture. Briefly, 0.5g of a faecal sample is immediately suspended in dilution buffer and 50ml 10⁸-diluted faecal sample are plated anaerobically on medium 0.05%glucose, 0.05% cellobiose, 0.05% soluble starch, 3.75% minerals, 0.025%L-cysteine HCl•H₂O, 0.0001% resazurin, 0.4% Na₂CO₃, 0.2% trypticase,0.05% yeast extract, 0.31% volatile fatty acid, 0.001% hemin, and 2.0%agar. Isolates are subcultured on Eggerth Gagnon (EG) agar supplementedwith 5% (v/v) horse blood. Isolates that contain Prevotella copri areidentified on the basis of containing a 16S nucleotide sequence commonto Prevotella_9 species X as described herein. Preferably the isolatecontains OTU000041, more preferably, a nucleic acid having SEQ ID No:1or SE ID No:2 nucleotide sequence. In this embodiment, it is preferredthat the Prevotella copri is isolated from the feces or stool of amother who contains Prevotella copri nucleic acid in her stool and whodoes not have offspring who have allergic disease. Such an individualmay be identified by the methods of the invention described above.

Prevotella copri strain, whether isolated from faeces, or otherwise maybe cultured in 100% CO₂ at 37° C. in EG media supplemented with horseblood. Alternatively, cells may be cultured in Columbia blood mediumsupplemented with 5% defibrinated sheep blood, or PYG medium (modified).The cells may be cultured to an optical density consistent with end of alogarithmic growth phase.

Prevotella including Prevotella derived from a culture method describedabove may be dried before, during or at completion of formulation. Thismay improve viability of Prevotella by reducing the water activity ofthe cells as well as improving the viability and stability offormulations that contain the cells. Prevotella may be dried so as todecrease the water or moisture content of Prevotella cells to about 1 to10%, preferably from about 2 to 8%, more preferably from about 2 to 5%.Below 1% there may be reduction in cell viability over long termstorage. Above 10% the water activity may be too high resulting inreduction in cell viability.

Prevotella may be dried by freeze drying (lyophilization), lowtemperature vacuum drying (LTVD)or spray drying, or combination of thesetechniques.

Freeze drying may involve freezing the liquid material in the Prevotellacells with further decreases of the chamber pressure enabling frozenwater to sublimate. The key advantage is that the drying step is lessdamaging than techniques that use higher drying temperatures.

A cryoprotectant may be used in a drying process described above such asfreeze drying where the purpose is to freeze water in the cells. Thepurpose the cryoprotectant is to maintain the viability of the cells asthe temperature approaches 0° C. or below. This is achieved by loweringthe freezing point of water and consequently its vapour pressure.Examples of cryoprotectants include those that are food grade and thosethat may permeate through the cell wall. Poly-alcohols such as glycerin,sorbitol and mannitol are examples of cryoprotectants. Othercryoprotectants include oligosaccharides such as inulin, starches anddextrin. Trehalose may be used with sugar alcohols, glycerol or certainproteins, particularly milk derived proteins as a cryoprotectant.

LTVD is based on the principle of creating a vacuum to decrease thepressure around the Prevotella cells below the vapour pressure of water,which decreases the boiling point of water inside the cells. Thiscondition increases the rate of evaporation of water from cells at atemperature that is lower than would otherwise apply if the desiredevaporation rate was to be obtained at standard atmospheric condition.One advantage of LVTD is that temperatures at which ice might form incells are not reached, so this lessens the likelihood of damage toPrevotella cells.

Spray drying is an atomization technology whereby a drying chamberreceives a liquid spray containing Prevotella cells which is rapidlyevaporated as soon as it encounters a hot air flow producing finelydried particles. Spray drying may involve the use of a stream which actsas an osmoprotectant to protect the Prevotella cells from over drying.These osmoprotectants may include trehalose, non fat milk solids, oradonitol. The osmoprotectants may encapsulate the Prevotella cells asdescribed further below.

During or after drying, Prevotella cells may be microencapsulated.Microencapsulation of Prevotella cells may assist in maintaining theviability of cells during or after drying. Further, microencapsulationmay assist in improving stability during storage of Prevotella cells orduring passage through the gastro-intestinal tract.

Where microencapsulation occurs during drying, the drying step may servethe dual purposes of reducing water content of cells and forming thestructure of the microcapsule.

Microencapsulation may take the form of monocore encapsulation in whicheach capsule contains a single cell, or polycore encapsulation in whicheach capsule contains more than one cell. A further form is a matrixencapsulation in which individual cells are entrapped within a polymericmaterial, examples of which include sugars, polysaccharides, proteinsand combinations thereof. Monocore or polycore encapsulated Prevotellacells may be entrapped within a polymeric matrix. A microcapsule mayhave a diameter in the range from 1 micron (monocore encapsulation)through to 1 mm (matrix encapsulation).

Carbohydrate based encapsulates may be used during a freeze drying orspray drying process. Alginate is a common microencapsulation materialdue to it being nontoxic, relatively cheap and its use in creatingmatrix microencapsulation in the form of beads. Calcium and sodiumalginate are the most widely used forms. Poly-1-lysine alginatecomposition has also been used for microencapsulation. Alginates aregenerally used at less than 5% by weight.

Alginate may be combined with cryoprotectants such as glycerol wherefreeze drying is involved in production, or where Prevotella cells arefrozen during storage after drying and encapsulation. Other compoundsthat may be used with alginate to improve survival include antioxidants(such as ascorbic acid) and buffering agents (phosphate containingbuffers).

Polysaccharides such as cellulose acetate phthalate, maltodextrin andmodified waxy maize starch have been used as microencapsulants, as havelow molecular weight sugars (lactose, trehalose, maltose, and sucrose)and poly-alcohols (mannitol and sorbitol).

The carbohydrate used for microencapsulation may be a prebiotic i.e. acompound or composition that provides growth enhancing effects, or is anutrient for Prevotella cells in the gastro-intestinal tract.

Protein based encapsulates may also be used during a preparative processfor drying cells. These include skim milk, casein and whey protein ornon-milk proteins. Plant based proteins such as soy protein has alsobeen used.

Prevotella cells normally inhabit the GI tract in healthy humanindividuals, including the stomach and duodenal and ileal regions of thesmall intestine. Endogenous Prevotella therefore has an ability tosurvive in low pH and bile containing environs.

The stability of cells in the gastro-intestinal tract may be enhanced orimproved by using a micro-encapsulant that can either minimize exposureto the environment, particularly so as to provide cells with sufficienttime to acclimatize to the environment. For example, a microcapsule maygradually expose cells to low pH or bile over a predetermined timeperiod thereby minimizing the likelihood of inducing shock in the cells.For this purpose, cells may be provided in the form of a monocore orpolycore microcapsule, or as a matrix microcapsule. Anyone of theseforms of microcapsule may be further provided with a coating in the formof a layer located on or about the microcapsule form to assist inmaintenance of viability of cells. The coated microcapsule may beprovided in the form of a tablet, a capsule or a bead suitable for oraladministration.

Enteric coats are often pH selective and allow for protection againstgastric pH and that subsequently dissolve in the more alkali intestinalenvironment. Various forms of hydroxypropyl methylcellulose (HPMC)including HPMC phthalate have been used to protect orally givenbacteria. High amylose starch, particularly chemically substitutedstarch such as carboxymethyl high amylose starch has also been used. Thechemical substitution may minimize degradation of starch in the gastricenvironment, and, being polysaccharide in nature, the starch is quicklydissolved by enzymatic hydrolysis upon reaching the small intestine.Starch has also been combined with chitosan to provide an entericcoating that may substantially resist degradation in the gastricenvironment and permit release of cells into the intestine or colon.

Compression coatings which erode over time in gastric and intestinalconditions may be utilized. For example a gel layer of alginate may beused alone or combined with other layers of coating formed fromchitosan, whey protein, poly-L-Lysine. Alginate may be mixed withglycerol and xanthan gum. Other microencapsulation systems may use milkprotein matrices that are induced by rennet, whey proteins, casein andlactoglobulin.

Generally, Prevotella cells are stored at room temperature, or 4-7° C.,or from 0 to 20° C., depending on prior processing and duration ofstorage.

Cells are generally dried according to a technique described abovebefore storage. If microencapsulation is implemented, it may benecessary to further dry encapsulated cells so as to remove residualwater introduced during encapsulation. Removal of water could be carriedout through treatments such as use of a desiccant.

Freeze or spray dried microcapsules having low water activity may bestored for no longer than about 8 to 12 weeks without significant impacton viability. Storage for up to 20 months may be possible at coldertemperatures from -20 to 7° C.

The viability of dried and/or encapsulated cells can be determined bycounting numbers of colony forming units on media described above. Thismay involve serial diluting from stock derived from a particular batchof Prevotella.

Generally it is preferred that Prevotella composition should havesufficient numbers of cells to provide from 10⁸ to 10⁹ cells to thegastro intestinal tract. Therefore where provided in the form of a unitdose composition (such as a tablet or capsule) a unit dose may have fromabout 1×10⁶ to 1×10¹¹ cfu of Prevotella.

The invention will now be described with reference to the following,non-limiting examples.

It will be understood that the invention disclosed and defined in thisspecification extends to all alternative combinations of two or moreindividual features mentioned or evident from the text or drawings. Allof these different combinations constitute various alternative aspectsof the invention.

Example 1 Study Outline

Using an unselected antenatal sampling frame, a birth cohort of 1074mother-infant pairs in the southeast of Australia was assembled. Infantswere excluded if they were born before 32 weeks of gestation, developeda serious illness in the first week of life, or had significantcongenital or genetic abnormalities. Women completed a food frequencyquestionnaire as described previously (McOrist, Abell et al. 2008) andprovided a faecal sample at approximately 36 weeks of pregnancy. Flowcytometry was conducted to enumerate immune cells on freshly collectedcord blood samples (i.e. at birth). Infants were reviewed in the firstdays of life and 1, 3, 6, 9 and 12 months after birth. Three case groups(food allergy, atopic eczema and atopic wheeze) were compared with arandomly selected subgroup of 324/894 (36%) infants who completed the1-year review.

Study Measures: Case Definitions

Food allergy: Skin prick allergy testing (SPT) was performed at 1-yearaccording to standard guidelines (Bernstein and Storms 1995). A positiveskin prick test was defined as a wheal diameter at least 2 mm greaterthan that produced by a negative control solution, measured at 15minutes. SPT was performed using Quintip® skin pricks to the followingallergens: cow’s milk, egg, peanut, sesame, cashew, dust mite(Dermatophagoides pteronyssinus 1), cat, dog, rye grass and alternariatenius (Stallergenes®). Infants who exhibited a positive SPT to any ofthe five foods tested were invited to attend a food allergy clinic forclinical assessment +/- oral food challenge. Infants with a clearhistory of an immediate- type reaction following exposure to a specificfood to which they were skin prick positive were classified as allergicto that food. In the absence of such history, oral food challenges foregg, peanut, sesame and cashew were undertaken regardless of the SPTwheal size (Osborne, Koplin et al. 2010) using standardized foodchallenge protocols (Koplin, Tang et al. 2011). A positive foodchallenge was defined according to the protocol established by theHealthNuts study (Osborne, Koplin et al. 2010).

Atopic wheeze: The combination of wheezing illnesses and atopicsensitisation during the first year of postnatal life is associated witha dramatically increased risk of persisting wheeze and asthma insubsequent childhood. Respiratory questionnaires were administered at 1,3, 6, 9 months and 1 year. At each review parents were provided with adefinition of wheeze and then asked whether their child had “wheeze orwhistling in the chest since the last review”. Atopic wheeze was definedas the presence of parent-reported wheeze during the first year of lifeplus a positive SPT (2 mm) to any of the food antigens or aeroallergens.

Atopic Eczema. Eczema questionnaires were administered at 1, 3, 6, 9months and 1 year; and clinical assessments were conducted at 1 month, 6months and 1 year. Eczema was defined according to the Modified UKworking party criteria for infants under 12 months (Williams, Burney etal. 1994, Fleming, Bodner et al. 2001). All infants had to have ahistory of itchy skin plus at least three of the following: a history ofdry skin, a family history of allergy, a history of skin rash affectingthe flexures or outer surfaces of the limbs or affecting the head orcheeks, visible dermatitis assessed during a study visit at either 1month, 6 months or 1 year (Ismail, Oppedisano et al. 2012). Atopiceczema was defined as the presence of eczema plus atopic sensitisation.

Study Measures: Collection and Processing of Maternal Stool SamplesStool Sample Collection

Stool samples were collected from pregnant women at 36 weeks gestation.Participants were provided with sterile specimen jars and detailedcollection instructions. The stool samples were then either: (i) placedinto an esky with ice blocks (supplied by BIS team) and broughtimmediately to the University Hospital, or (ii) stored in the householdfreezer (approximately -20° C.) until delivery to the UniversityHospital in an esky with ice blocks. Once samples reached the UniversityHospital the laboratory staff recorded all the collection details andthawed the samples. They were then aliquoted into 4-6 storage tubes andstored in a -80° C. ultra low temperature freezer until processing.

Protocol for DNA Isolation From Stool Samples

The microbial DNA was extracted using the PowerSoil® DNA Isolation Kit,Cat# 12888-100. The protocol followed the manufacturers instructions andincluded a minor preparatory pre-lysis step for improved stooldisaggregation.

1. Remove an aliquot of stool from the -80° C. freezer and thawpartially.

2. Scrape a small portion (approx. 100-250 mg) of the stool sample andimmediately return the remainder of the stool sample to the freezer.

3. Weigh the tube + scrape of stool to determine the sample weight.Record in the table below.

4. Check Solution C1. If Solution C1 is precipitated, heat solution to60° C. or warm in the 37° C. incubator until dissolved before use.

5. Add 250 ul of MO BIO Lysis Solution C1 and 250 uL of PowerBeadsolution/buffer from Labelled PowerBead tube. Vortex the tube at maximumspeed for 2 minutes to solubilize and pre-lyse the stool sample. Performa quick spin to remove bubbles.

6. Pipette the total amount of Supernatant (leave the precipitateincluding fibre) into the labelled MO BIO PowerBead tube that alreadyremoved 250 µL of MO BIO solution/buffer. Vortex for 10 seconds.

7. Heat the tubes in a 90 C heat block for 5 minutes.

8. Secure the PowerBead tubes horizontally on the MO BIO vortex adaptertube holder and vortex at maximum speed for 10 minutes.

9. Centrifuge tubes at 9,800 g for 1 minute at room temperature (approx.22 C).

10. Transfer 750 ul of the supernatant to a clean labelled 2 mlcollection tube (provided in kit).

11. Add 400 ul of Solution C2 (for removal of inhibitors) and vortexwell for 10 seconds.

12. Incubate at 4 C (in the cool-block kept in the fridge) for 5minutes.

13. Centrifuge the tubes at room temperature for 2 minute at 14,000 g.

14. Avoiding the pellet, transfer 1000 ul of supernatant to a cleanlabelled 2 ml collection tube.

15. Add 600ul of Solution C3 (for further removal of inhibitors) andvortex briefly. Incubate at 4° C. (in the cool-block in the fridge) for5 minutes.

16. Centrifuge the tubes at room temperature for 2 minute at 14,000 g.

17. Avoiding the pellet, transfer 2 × 600 ul of supernatant into 2 ×clean labelled 2 ml collection tube.

18. Shake to mix Solution C4 (DNA binding) before use. Add 1000 ul ofSolution C4 to the supernatant in each tube and vortex well for 10seconds.

19. Load 650 ul (5 separate times) on to a labelled spin filter andcentrifuge at 12,200 g for 1 minute at room temperature. Discard theflow through and add the additional volumes and centrifuge again untilall the sample has passed through the filter.

20. Add 500 ul of Solution C5 (ethanol wash) directly on to the filterand centrifuge at room temperature for 1 minute at 10,000 g.

21. Discard the flow through.

22. Repeat step 18. Use a new labelled collection tube and centrifugeagain at room temperature for 2 minute at 10,000 g (this removes anyresidual ethanol from the DNA on the filter).

23. Carefully place spin filter in a clean labelled FINAL 2 mlcollection tube.

24. Add 60ul of Solution C6 (elution buffer - this can be warmed in the37° C. incubator) to the centre of the white filter membrane for elutionof the DNA.

25. Cap the tube and allow it to sit at room temperature for 5-10minutes.

26. Centrifuge at room temperature for 1 minute at 10,000 g.

27. Reload eluted DNA onto filter for higher yield.

28. Re-centrifuge at room temperature for 2 minute at 10,000 g.

29. Discard the spin filter and cap the tube.

30. Measure DNA conc using the Nanodrop and then store tubes of DNA in-80° C. freezer.

DNA samples were diluted to 10 ng/µl and shipped on dry ice to JCVI for16S sequencing.

Study Measures: Microbiome Composition

Region V4 of the 16S rDNA gene was selected using forward and reversePCR primers GTGCCAGCMGCCGCGGTAA and GGACTACHVGGGTWTCTAAT respectively.Dual index primers were attached to enable multiplex sequencing. Theresulting libraries were sequenced on the Illumina MiSeq platformproducing paired-end sequences. De-multiplexing and low-quality readfiltering were performed in the MiSeq software prior to obtaining FASTQfiles describing the reads produced by each sample. Correspondingpaired-end reads were merged, filtered (to remove merged reads withmismatches, too many or too few base pairs), clustered into OTUs at 97%identity, OTU representative sequences identified and chimeras removed,all using the Usearch software suite. The mothur software suite was usedto assign representative sequences to taxa described in the SILVA v123Nr99 taxonomic database. The final descriptions of OTUs present in eachsample were composed in the Usearch suite.

The above procedure was done with samples of 36 week maternal stool aswell as 1, 6 and 12 month infant stools and was done in three separatesequencing runs. This application only relates to maternal samples.

Study Measures: Statistical Analyses

The outcome of microbiome composition analysis is an “OTU table” and a“taxonomy table”. The OTU table lists, for each sample, the number oftimes a DNA sequence corresponding to each OTU has been detected in thatsample. The taxonomy table gives a taxonomic assignment for each OTU.

Comparison was made between the distributions of OTUs between stoolsamples from mothers whose infants went on to be diagnosed asfood-allergic, and those whose infants returned negative skin pricktests, at 12 months of age. These comparisons were adjusted for thefollowing process covariates (i) which (of three) batches the sample wassequenced in, (ii) whether the sample had been provided to us fresh orfrozen, and (iii) the length of time the sample had been stored at -80 Cbefore DNA was extracted.

The statistical software programme R was used for all analyses. Thepackage phyloseq was used to manage the data. The data were furtheranalysed using the packages Voom, edgeR, DESeq2 and metagenomeSeq.Univariate analyses were conducted using all four packages. Voom andDESeq2 for were used in the adjusted analyses.

Results: Maternal 16 s rDNA Data

We obtained a median 4025 OTUs from 434 samples of maternal origin.Based on an inspection of the data we excluded samples with fewer than650 OTUs. We also excluded samples which were technical replicates. Withreference to the food allergy analyses, we excluded samples fromparticipants who did not have a definitive determination of food allergystatus, or had been included for sequencing other than on the basis ofsubcohort membership or challenge-proven food allergy.

Using Voom to identify the OTUs most different between thechallenge-proven food allergic and not allergic groups identified OTUs41 and 697 as having the best support (p-values adjusted for multipletesting 0.003 (FIG. 4 )and 0.009 respectively; next lowest p-value0.19). Both these OTUs were classified as Prevotella_9, a subgroup ofPrevotella containing two described species, Prevotella copri and P.paludivivens. Combining OTUs at the genus level, the Prevotella_9subgroup is different between phenotype groups (p=0.005)(FIG. 3 ). Insummary, 48 out of 232 controls, versus 5 of 59 food allergics, hadPrevotella_9 DNA detected, with a total of 33000 detections in thecontrols versus 44 in the food allergics. Combining subgrouped genera(e.g. all Prevotella subgroups into one, and similarly for other genuslevel taxa with such subgroups) weakens the evidence (p=0.4)(FIG. 4 ).

An adjusted analysis to consider the effects of duration of storage,whether the sample had been provided to us fresh or frozen, and batcheffects showed there was still evidence that Prevotella_9 was differentbetween the allergy groups (p=0.003) and a similar magnitude of effect.

We also examined the evidence for OTUs different between the atopicwheeze group and others. For this analysis we included only our randomsub cohort. Here again the Prevotella_9 subgroup had good evidence of adifference between allergic and control groups (p=0.003): it is presentin 59 of 262 control samples with 40000 total occurrences, while thereis a single occurrence in one member of the atopic wheeze group (14samples)(FIG. 5 ).

Similarly we looked for differences between the atopic eczema group andothers. Here again the Prevotella_9 subgroup had some evidence of adifference between allergic and control groups(p=0.07); present in 57 of264 control samples with 39000 occurrences, and a single occurrence ineach of two members of the atopic eczema group (FIG. 6 ).

Results: Confirmation of the Identity of OTU000041

The DNA sequence code of OTU000041 was:

TACGGAAGGTCCGGGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCGTGTTGTGAAATGTAGACGCTCAACGTCTGCACTGCAGCGCGAACTGGTTTCCTTGAGTACGCACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATCGAAC AGG (SEQ ID NO: 1)

The National Centre for Biotechnology Information BLAST similaritysearch for OTU000041 in the 16S ribosomal RNA sequences (Bacteria andArchacea) indicates 100% homology with the species Prevotella copristrain JCM 13464, the sequence alignment being shown in FIG. 1 . Theregion of homology is in the V4 section of the gene as shown in FIG. 2 .

Results: Confirmation of the Identity of OTU000697

The DNA sequence code of OTU000697 was:

TACGTATGGTGCAAGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCGTGTTGTGAAATGTAGATGCTCAACATCTGAACTGCAGCGCGAACTGGTTTCCTTGAGTACGCACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATCGAAC AGG (SEQ ID NO: 2)

The sequence is 98% similar to the NR_113411.1 sequence shown in FIG. 1and to SEQ ID NO: 1).

Example 2 Study Outline: Validation of PCR Assays for the Identificationof Prevotella 9 Species From Faecal Samples

Based on the 16 s DNA sequencing data presented above, we have designedPCR assays for the identification of the relevant Prevotella 9 speciesfrom faecal samples. Primers were designed to amplify DNA regions thatmatch and discriminate OTU000041 and OTU000697. The base pair sequencesfor the PCR primers are as follows: OTU_41For

TACGGAAGGTCCGGGCGTTAT

OTU_41 Rev

AGTGCAGACGTTGAGCGTCTA

OTU_697 For

TACGTATGGTGCAAGCGTT

OTU_697 Rev

GCAGTTCAGATGTTGAGCATC

WITHOUT LIMITATION THE INVENTION MAY BE SUMMARISED BY THE FOLLOWINGITEMS

1. A composition formulated for human consumption (as defined herein)comprising, or consisting of bacteria that is Prevotella_9 (as describedherein).

2. A composition formulated for human consumption (as defined herein)comprising, or consisting of bacteria comprising:

-   a 16S rDNA sequence shown in SEQ ID No: 1; or-   a 16S rDNA sequence having at least 97% identity, preferably 98%    identity, preferably 99% identity with the sequence shown in SEQ ID    No: 1; or-   a 16S rDNA sequence shown in SEQ ID No: 2; or-   a 16S rDNA sequence having at least 97% identity, preferably 98%    identity, preferably 99% identity with the sequence shown in SEQ ID    No:2.

3. A composition according to item 1 or item 2 wherein the bacteria isPrevotella copri.

4. A composition according to any one of items 1 to 3 wherein thecomposition further comprises a further ingredient that is beneficialfor a pregnant or lactating woman.

5. A composition according to item 4 wherein the further ingredient is avitamin selected from the group consisting of: vitamin B1 (thiamine),vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B5 (pantothenicacid), vitamin B6 (pyridoxine), folic acid, vitamin B12(cyanocobalamine), biotin, choline, and vitamin C, vitamin D3, vitamin Eand vitamin K.

6. A composition according to item 4 or item 5 wherein the furtheringredient is a mineral selected from the group consisting of calcium,phosphorus, zinc, iodine, iron, manganese, selenium, copper, andmagnesium.

7. A composition according to item 4 or item 5 or item 6 wherein thefurther ingredient is a long chain polyunsaturated fatty acid (LC-PUFA),preferably eicosapentaenoic acids and/or acyl chain (EPA),docosahexaenoic acid and/or acyl chain (DHA) and arachidonic acid and/oracyl chain (AA).

8. A composition according to item 4 or item 5 or item 6 or item 7wherein the composition further comprises a further bacteria species,preferably Lactobacillus accidophilus group, L. rhamnosus, L. casei, L.paracasei, L. plantarum, L. reuteri, L. fermentum, Bifidobacteriuminfantis, B. animalis subsp. lactis, B. breve, B. longum and B. bifidum.

9. A composition according to item 4 or item 5 or item 6 or item 7 oritem 8 wherein the composition further comprises a non-digestibleoligosaccharide, preferably selected from the group consisting of:fructo-oligosaccharides (such as inulin), galacto-oligosaccharides (suchas transgalacto-oligosaccharides or beta-galacto-oligisaccharides),gluco-oligosaccharides (such as gentio-, nigero- andcyclodextrin-oligosaccharides), arabino-oligosaccharides,mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides,arabinogalacto-oligosaccharides, glucomanno-oligosaccharides,galactomanno-oligosaccharides, sialic acid oligosaccharides and uronicacid oligosaccharides.

10. A composition according to item 4 or item 5 or item 6 or item 7 oritem 8 or item 9 wherein the composition further comprises amacronutrient selected from the group consisting of: protein, fat anddigestible carbohydrate.

11. A composition according to any one of items 1 to 10 provided in theform of a unit dose composition, preferably as a tablet, or capsule,caplet, bead or powder.

12. A composition according to item 11 wherein the unit dose may havefrom about 1×10⁶ to 1×10¹¹ cfu of Prevotella

13. A composition conditioned by a bacteria of a composition describedabove, preferably by Prevotella copri.

14. A composition according to item 13 further comprising a furtheringredient that is beneficial for a pregnant or lactating woman selectedfrom the group consisting of a mineral, a vitamin, a long chainpolyunsaturated fatty acid, a non-digestible oligosaccharide, or amacronutrient selected from a digestible carbohydrate, a fat or oil andprotein.

15. A composition according to any one of the preceding items whereinthe composition comprises dried bacteria.

16. A composition according to any one the preceding items wherein thebacteria are microencapsulated and/or coated with an enteric coating.

17. A composition according to any one of the preceding items whereinthe bacteria may be provided in a form enabling re-hydration beforeadministration.

18. A composition according to any one of the preceding items whereinthe composition may further comprise a desiccant, an osmoprotectant or acryoprotectant.

19. A method for conditioning a female individual (as defined herein) tominimize the likelihood of development of allergy in offspring orprogeny of the female individual comprising the step of administering acomposition according to any one of the preceding items to the femaleindividual thereby minimizing the likelihood of development of allergyin progeny of the female.

20. A composition according to any one of the preceding items for use byadministration to a female individual in minimizing the likelihood ofdevelopment of allergy in progeny of the female individual.

21. A use of a composition according to any one of the preceding itemsin a female individual to minimize the likelihood of development ofallergy in progeny of the female individual.

22. A method for determining the likelihood of a female individualforming offspring having allergic disease comprising the followingsteps:

-   -providing a control describing the relative abundance of Prevotella    16S rDNA in the stool of a mother who has offspring who do not have    allergic disease;-   obtaining a sample from the female individual for whom the    likelihood of forming offspring having allergic disease is to be    determined, thereby forming a test sample;-   comparing the test sample with the control to assess whether the    test sample has a relative abundance of Prevotella 16S rDNA as    described in the control;-   determining that the female individual has a low likelihood of    forming offspring having allergic disease where the test sample has    a relative abundance of Prevotella 16S rDNA as described in the    control-   determining that the female individual has a high likelihood of    forming offspring having allergic disease where the test sample has    a relative abundance of Prevotella 16S DNA that is not described in    the control.

Nucleotide Sequences

TACGGAAGGTCCGGGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCGTGTTGTGAAATGTAGACGCTCAACGTCTGCACTGCAGCGCGAACTGGTTTCCTTGAGTACGCACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATCGAAC AGG (SEQ ID NO: 1)

TACGTATGGTGCAAGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCGTGTTGTGAAATGTAGATGCTCAACATCTGAACTGCAGCGCGAACTGGTTTCCTTGAGTACGCACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATCGAAC AGG (SEQ ID NO: 2)

TACGGAAGGTCCGGGCGTTAT (SEQ ID NO: 3)

AGTGCAGACGTTGAGCGTCTA (SEQ ID NO: 4)

TACGTATGGTGCAAGCGTT (SEQ ID NO: 5)

GCAGTTCAGATGTTGAGCATC (SEQ ID NO: 6)

TACGGAAGGTCCGGGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCGTGTTGTGAAATGTAGACGCTCAACGTCTGCACTGCAGCGCGAACTGGTTTCCTTGAGTACGCACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATCGAAC AG (SEQ ID No: 7)

AGAGTTTGATCCTGGCTCAGGATGAACGCTAGCTACAGGCTTAACACATGCAAG TCGAGGGGAAACGACATCGAAAGCTTGCTTTTGATGGGCGTCGACCGGCGCACGGGTGAG TAACGCGTATCCAACCTGCCCAYCACTTGGGGATAACCTTGCGAAAGTAAGACTAATACC CAATGATATCTCTAGAAGACATCTGAAAGAGATTAAAGATTTATCGGTGATGGATGGGGA TGCGTCTGATTAGCTTGTTGGCGGGGTAACGGCCCACCAAGGCGACGATCAGTAGGGGTT CTGAGAGGAAGGTCCCCCACATTGGAACTGAGACACGGTCCAAACTCCTACGGGAGGCAG CAGTGAGGAATATTGGTCAATGGRCGAGAGCCTGAACCAGCCAAGTAGCGTGCAGGATGA CGGCCCTATGGGTTGTAAACTGCTTTTATAAGGGAATAAAGTGAGCCTCGTGAGGCTTTTT GCATGTACCTTATGAATAAGGACCGGCTAATTCCGTGCCAGCAGCCGCGGTAATACGGA AGGTCCGGGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCG TGTTGTGAAATGTAGACGCTCAACGTCTGCACTGCAGCGCGAACTGGTTTCCTTGAGTACG CACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTC CGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATC GAACAGGATTAGATACCCTGGTAGTCCGCACGGTAAACGATGGATGCCCGCTGTTGGTCTG AACAGGTCAGCGGCCAAGCGAAAGCATTAAGCATCCCACCTGGGGAGTACGCCGGCAAC GGTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGAGGAACATGTGGTTTAATTC GATGATACGCGAGGAAACCTTACCCGGGCTTGAATTGCAGAGGAAGGATTTGGAGACAAT GACGCCCTTCGGGGYCTCTGTGAAGGTGCTGCATGGTTGTCGTCAGCTCGTGCCGTGAGGT GTCGGCTTAAGTGCCATAACGAGCGCAACCCCTCTCCTTAGTTGCCATCAGGTYAAGCTG GGCACTCTGGGGACACTGCCACCGTAAGGTGTGAGGAAGGTGGGGATGACGTCAAATCA GCACGGCCCTTACGTCCGGGGCTACACACGTGTTACAATGGCAGGTACAGAGAGACGGTY SCYYGYAAAGTSGATCAAATCCTTAAAGCCTGTCTCAGTTCGGACTGGGGTCTGCAACCCG ACCCCACGAAGCTGGATTCGCTAGTAATCGCGCATCAGCCATGGCGCGGTGAATACGTT CCCGGGCCTTGTACACACCGCCCGTCAAGCCATGAAAGCCGGGGGCGCCTAAAGTCCGTG ACCGTAAGGAGCGGCCTAGGGCGAAACTGGTAATTGGGGCTAAGTCGTAACAAGGTAACC (SEQ ID No: 8)

AGAGTTTGATCCTGGCTCAGGATGAACGCTAGCTACAGGCTTAACACATGCAAG TCGAGGGGAAACGACATCGAAAGCTTGCTTTTGATGGGCGTCGACCGGCGCACGGGTGAG TAACGCGTATCCAACCTGCCCAYCACTTGGGGATAACCTTGCGAAAGTAAGACTAATACC CAATGATATCTCTAGAAGACATCTGAAAGAGATTAAAGATTTATCGGTGATGGATGGGGA TGCGTCTGATTAGCTTGTTGGCGGGGTAACGGCCCACCAAGGCGACGATCAGTAGGGGTT CTGAGAGGAAGGTCCCCCACATTGGAACTGAGACACGGTCCAAACTCCTACGGGAGGCAG CAGTGAGGAATATTGGTCAATGGRCGAGAGYCTGAACCAGCCAAGTAGCGTGCAGGAWG ACGGCCCTATGGGTTGTAAACTGCTTTTATAAGGGAATAAAGTGAGCCTCGTGAGRCTTTTT GCATGTACCTTATGAATAAGGACCGGCTAATTCCGTGCCAGCAGCCGCGGTAATACGGA AGGTCCGGGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCG TGTTGTGAAATGTAGACGCTCAACGTCTGCACTGCAGCGCGAACTGGTTTCCTTGAGTACG CACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTC CGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATC GAACAGGATTAGATACCCTGGTAGTCCGCACGGTAAACGATGGATGCCCGCTGTTGGTCTG AACAGGTCAGCGGCCAAGCGAAAGCATTAAGCATCCCACCTGGGGGAGTACGCCGGCAA CGGTGAAACTCAAAGGAATTGACGGGGCCCGCACAAGCGGAGGAACATGTGGTTAATTCG ATGATACGCGAGGAACCTTACCCGGGCTTGAATTGCAGAGGAAGGATTGGAGACAATGAC GCCCTTCGGGGCCTCTGTGAAGGTGCTGCATGGTTGTCGTCAGCTCGTGCCGTGAGGTGTC GGCTTAAGTGCCATAACGAGCGCAACCCCTCTCCTTAGTTGCCATCAGGTYAWGCTGGG CACTCTGGGGACACTGCCACCGTAAGGTGTGAGGAAGGTGGGGATGACGTCAAATCAGCA YGGCCCTTACGTCCGGGGCTACACACGTGTTACAATGGCAGGTACAGAGAGACGGTYSYW YGYAARWTSGATCAAATCCTTAAAGCCTGTCTCAGTTCGGACTGGGGTCTGCAACCCGACC CCACGAAGCTGGATTCGCTAGTAATCGCGCATCAGCCATGGCGCGGTGAATACGTTCCCG GGCCTTGTACACACCGCCCGTCAAGCCATGAAAGCCGGGGGCGCCTAAAGTCCGTGACC GTAAGGAGCGGCCTAGGGCGAAACTGGTAATTGGGGCTAAGTCGTAACAAGGTAACC (SEQ ID No: 9)

AGAGTTTGATCCTGGCTCAGGATGAACGCTAGCTACAGGCTTAACACATGCAAG TCGAGGGGAAACGACATCGAAAGCTTGCTTTTGATGGGCGTCGACCGGCGCACGGGTGAG TAACGCGTATCCAACCTGCCCACCACTTGGGGATAACCTTGCGAAAGTAAGACTAATACCC AATGATATCTCTAGAAGACATCTGAAAGAGATTAAAGATTTATCGGTGATGGATGGGGA TGCGTCTGATTAGCTTGTTGGCGGGGTAACGGCCCACCAAGGCGACGATCAGTAGGGGTT CTGAGAGGAAGGTCCCCCACATTGGAACTGAGACACGGTCCAAACTCCTACGGGAGGCAG CAGTGAGGAATATTGGTCAATGGRCGAGAGYCTGAACCAGCCAAGTAGCGTGCAGGAWG ACGGCCCTATGGGTTGTAAACTGCTTTTATAAGGGAATAAAGTGAGCCTCGTGAGRCTTTTT GCATGTACCTTATGAATAAGGACCGGCTAATTCCGTGCCAGCAGCCGCGGTAATACGGA AGGTCCGGGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCG TGTTGTGAAATGTAGACGCTCAACGTCTGCACTGCAGCGCGAACTGGTTTCCTTGAGTACG CACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTC CGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATC GAACAGGATTAGATACCCTGGTAGTCCGCACGGTAAACGATGGATGCCCGCTGTTGGTCTG AACAGGTCAGCGGCCAAGCGAAAGCATTAAGCATCCCACCTGGGGAGTACGCCGGCAAC GGTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGAGGAACATGTGGTTTAATTC GATGATACGCGAGGAACCTTACCCGGGCTTGAATTGCAGAGGAAGGATTTGGAGACAATG ACGCCCTTCGGGGYCTCTGTGAANGTGCTGCATGGTTGTCGTCAGCTCGTGCCGTGAGGTG TCGGCTTAAGTGCCATAACGAGCGCAACCCCTCTCCTTAGTTGCCATCAGGTCAAGCTGG GCACTCTGGGGACACTGCCACCGTAAGGTGTGAGGAAGGTGGGGATGACGTCAAATCAG CACGGCCCTTACGTCCGGGGCTACACACGTGTTACAATGGCAGGTACAGAGAGACGGTYS YWTGYAARWTSGATCAAATCCTTAAAGCCTGTCTCAGTTCGGACTGGGGTCTGCAACCCGA CCCCACGAAGCTGGATTCGCTAGTAATCGCGCATCAGCCATGGCGCGGTGAATACGTTCC CGGGCCTTGTACACACCGCCCGTCAAGCCATGAAAGCCGGGGGCGCCTAAAGTCCGTGA CCGTAAGGAGCGGCCTAGGGCGAAACTGGTAATTGGGGCTAAGTCGTAACAAGGTAACC (SEQ ID No: 10)

AGAGTTTGATCCTGGCTCAGGATGAACGCTAGCTACAGGCTTAACACATGCAAG TCGAGGGGAAACGACATCGAAAGCTTGCTTTTGATGGGCGTCGACCGGCGCACGGGTGAG TAACGCGTATCCAACCTGCCCAYCACTTGGGGATAACCTTGCGAAAGTAAGACTAATACC CAATGATATCTCTAGAAGACATCTGAAAGAGATTAAAGATTTATCGGTGATGGATGGGGA TGCGTCTGATTAGCTTGTTGGCGGGGTAACGGCCCACCAAGGCGACGATCAGTAGGGGTT CTGAGAGGAAGGTCCCCCACATTGGAACTGAGACACGGTCCAAACTCCTACGGGAGGCAG CAGTGAGGAATATTGGTCAATGGRCGAGAGYCTGAACCAGCCAAGTAGCGTGCAGGATGA CGGCCCTATGGGTTGTAAACTGCTTTTATAAGGGAATAAAGTGAGCCTCGTGAGRCTTTTT GCATGTACCTTATGAATAAGGACCGGCTAATTCCGTGCCAGCAGCCGCGGTAATACGGA AGGTCCGGGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCG TGTTGTGAAATGTAGACGCTCAACGTCTGCACTGCAGCGCGAACTGGTTTCCTTGAGTACG CACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTC CGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATC GAACAGGATTAGATACCCTGGTAGTCCGCACGGTAAACGATGGATGCCCGCTGTTGGTCTG AACAGGTCAGCGGCCAAGCGAAAGCATTAAGCATCCCACCTGGGGAGTACGCCGGCAAC GGTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGAGGAACATGTGGTTTAATTC GATGATACGCGAGGAACCTTACCCGGGCTTGAATTGCAGAGGAAGGATTTGGAGACAATG ACGCCCTTCGGGGYCTCTGTGAAGGTGCTGCATGGTTGTCGTCAGCTCGTGCCGTGAGGTG TCGGCTTAAGTGCCATAACGAGCGCAACCCCTCTCCTTAGTTGCCATCAGGTYAAGCTGG GCACTCTGGGGACACTGCCACCGTAAGGTGTGAGGAAGGTGGGGATGACGTCAAATCAG CACGGCCCTTACGTCCGGGGCTACACACGTGTTACAATGGCAGGTACAGAGAGACGGTYS YWYGYAARWTSGATCAAATCCTTAAAGCCTGTCTCAGTTCGGACTGGGGTCTGCAACCCGA CCCCACGAAGCTGGATTCGCTAGTAATCGCGCATCAGCCATGGCGCGGTGAATACGTTCC CGGGCCTTGTACACACCGCCCGTCAAGCCATGAAAGCCGGGGGCGCCTAAAGTCCGTGA CCGTAAGGAGCGGCCTAGGGCGAAACTGGTAATTGGGGCTAAGTCGTAACAAGGTAACC (SEQ ID No: 11)

AGAGTTTGATCCTGGCTCAGGATGAACGCTAGCTACAGGCTTAACACATGCAAG TCGAGGGGAAACGACATCGAAAGCTTGCTTTTGATGGGCGTCGACCGGCGCACGGGTGAG TAACGCGTATCCAACCTGCCCACCACTTGGGGATAACCTTGCGAAAGTAAGACTAATACCC AATGATATCTCTAGAAGACATCTGAAAGAGATTAAAGATTTATCGGTGATGGATGGGGA TGCGTCTGATTAGCTTGTTGGCGGGGTAACGGCCCACCAAGGCGACGATCAGTAGGGGTT CTGAGAGGAAGGTCCCCCACATTGGAACTGAGACACGGTCCAAACTCCTACGGGAGGCAG CAGTGAGGAATATTGGTCAATGGRCGAGAGYCTGAACCAGCCAAGTAGCGTGCAGGAWG ACGGCCCTATGGGTTGTAAACTGCTTTTATAAGGGAATAAAGTGAGYCTCGTGAGRCTTTTT GCATGTACCTTATGAATAAGGACCGGCTAATTCCGTGCCAGCAGCCGCGGTAATACGGA AGGTCCGGGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGCCGGAGATTAAGCG TGTTGTGAAATGTAGACGCTCAACGTCTGCACTGCAGCGCGAACTGGTTTCCTTGAGTACG CACAAAGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTC CGATTGCGAAGGCAGCTCACTGGAGCGCAACTGACGCTGAAGCTCGAAAGTGCGGGTATC GAACAGGATTAGATACCCTGGTAGTCCGCACGGTAAACGATGGATGCCCGCTGTTGGTCTG AACAGGTCAGCGGCCAAGCGAAAGCATTAAGCATCCCACCTGGGGAGTACGCCGGCAAC GGTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGAGGAACATGTGGTTTAATTC GATGATACGCGAGGAACCTTACCCGGGCTTGAATTGCAGAGGAAGGATTTGGAGACAATG ACGCCCTTCGGGGCCTCTGTGAAGGTGCTGCATGGTTGTCGTCAGCTCGTGCCGTGAGGTG TCGGCTTAAGTGCCATAACGAGCGCAACCCCTCTCCTTAGTTGCCATCAGGTYAAGCTGG GCACTCTGGGGACACTGCCACCGTAAGGTGTGAGGAAGGTGGGGATGACGTCAAATCAG CACGGCCCTTACGTCCGGGGCTACACACGTGTTACAATGGCAGGTACAGAGAGACGGTYS YWTGYAARWWSGATCAAATCCTTAAAGCCTGTCTCAGTTCGGACTGGGGTCTGCAACCCG ACCCCACGAAGCTGGATTCGCTAGTAATCGCGCATCAGCCATGGCGCGGTGAATACGTTCC CGGGCCTTGTACACACCGCCCGTCAAGCCATGAAAGCCGGGGGCGCCTAAAGTCCGTGA CCGTAAGGAGCGGCCTAGGGCGAAACTGGTAATTGGGGCTAAGTCGTAACAAGGTAACC (SEQ ID No: 12)

REFERENCES

-   Williams, H. C., P. G. Burney, A. C. Pembroke and R. J. Hay (1994).    “The U.K. Working Party’s Diagnostic Criteria for Atopic    Dermatitis. III. Independent hospital validation.” Br J Dermatol    131(3): 406-416.-   Fleming, S., C. Bodner, G. Devereux, G. Russell, D. Campbell, D.    Godden and A. Seaton (2001). “An application of the United Kingdom    Working Party diagnostic criteria for atopic dermatitis in Scottish    infants.” J Invest Dermatol 117(6): 1526-1530.-   McOrist, A. L., G. C. Abell, C. Cooke and K. Nyland (2008).-   Bernstein, I. L. and W. W. Storms (1995). “Practice parameters for    allergy diagnostic testing. Joint Task Force on Practice Parameters    for the Diagnosis and Treatment of Asthma.The American Academy of    Allergy, Asthma and Immunology and the American College of Allergy,    Asthma and Immunology.” Ann Allergy Asthma Immunol 75(6 Pt 2):    543-625.-   Koplin, J. J., M. L. Tang, P. E. Martin, N. J. Osborne, A. J.    Lowe, A. L. Ponsonby, M. N. Robinson, D. Tey, L. Thiele, D. J.    Hill, L. C. Gurrin, M. Wake, S. C. Dharmage and K. J. Allen (2011).    “Predetermined challenge eligibility and cessation criteria for oral    food challenges in the HealthNuts population-based study of    infants.” J Allergy Clin Immunol 129(4): 1145-1147.-   Osborne, N. J., J. J. Koplin, P. E. Martin, L. C. Gurrin, L.    Thiele, M. L. Tang, A. L. Ponsonby, S. C. Dharmage, K. J. Allen    and I. HealthNuts Study (2010). “The HealthNuts population-based    study of paediatric food allergy: validity, safety and    acceptability.” Clin Exp Allergy 40(10): 1516-1522.-   (1993). “Severity scoring of atopic dermatitis: the SCORAD index.    Consensus Report of the European Task Force on Atopic Dermatitis.”    Dermatology 186(1): 23-31.-   Ismail, I. H., F. Oppedisano, S. J. Joseph, R. J. Boyle, P. V.    Licciardi, R. M. Robins-Browne and M. L. Tang (2012). “Reduced gut    microbial diversity in early life is associated with later    development of eczema but not atopy in high-risk infants.” Pediatr    Allergy Immunol 23(7): 674-681.-   Rubin, D. B. and R. J. Little (2002). “Statistical analysis with    missing data.” Hoboken, NJ: J Wiley & Sons.-   Usearch: Edgar,RC (2010) Search and clustering orders of magnitude    faster than BLAST, Bioinformatics 26(19), 2460-2461. doi:    10.1093/bioinformatics/btq461-   Mothur: Schloss, P.D., et al., Introducing mothur: Open-source,    platform-independent, community-supported software for describing    and comparing microbial communities. Appl Environ Microbiol, 2009.    75(23):7537-41.-   SILVA: Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P,    Peplies J, Glöckner FO (2013) The SILVA ribosomal RNA gene database    project: improved data processing and web-based tools. Nucl. Acids    Res. 41 (D1): D590-D596.-   R: R Core Team (2016). R: A language and environment for statistical    computing. R Foundation for Statistical Computing, Vienna, Austria.    world-wide-web at R-project.org/-   phyloseq: phyloseq: An R package for reproducible interactive    analysis and graphics of microbiome census data. Paul J. McMurdie    and Susan Holmes (2013) PLoS ONE 8(4):e61217.-   voom: Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi,    W., and Smyth, G.K. (2015). limma powers differential expression    analyses for RNA-sequencing and microarray studies. Nucleic Acids    Research 43(7), e47.-   edgeR: Robinson MD, McCarthy DJ and Smyth GK (2010). edgeR: a    Bioconductor package for differential expression analysis of digital    gene expression data. Bioinformatics 26, 139-140-   McCarthy DJ, Chen Y and Smyth GK (2012). Differential expression    analysis of multifactor RNA-Seq experiments with respect to    biological variation. Nucleic Acids Research 40, 4288-4297-   DESeq2: Michael I Love, Wolfgang Huber and Simon Anders (2014):    Moderated estimation of fold change and dispersion for RNA-Seq data    with DESeq2. Genome Biology 15, 550-   metagenomeSeq: JN Paulson, OC Stine, HC Bravo, M Pop. Differential    abundance analysis for microbial marker-gene surveys. Nat Meth    Accepted-   Altschul, S.F., Gish, W., Miller. W., Myers, E.W. & Lipman.    D.J. (1990) “Basic local alignment search tool.” J. Mol. Biol.    215:403-410. PubMed-   Gish, W. & States, D.J. (1993) “Identification of protein coding    regions by database similarity search.” Nature Genet. 3:266-272.    PubMed-   Madden, T.L., Tatusov, R.L. & Zhang, J. (1996) “Applications of    network BLAST server” Meth. Enzymol. 266:131-141. PubMed-   Altschul, S.F., Madden, T.L. Schäffer, A.A., Zhang, J., Zhang, Z.,    Miller, W. & Lipman, D.J. (1997) “Gapped BLAST and PSI-BLAST: a new    generation of protein database search programs.” Nucleic Acids Res    25.3389-3402. PubMed-   Zhang Z, Schwartz S., Wagner L., & Miller W (2000), “A greedy    algorithm for aligning DNA sequences” J Comput Biol 2000;    7(1-2):203-14. PubMed-   Zhang, J. & Madden, T.L. (1997) “PowerBLAST: A new network BLAST    application for interactive or automated sequence analysis and    annotation.” Genome Res. 7:649-656. PubMed-   Morgulis A., Coulouris G., Raytselis Y., Madden T L., Agarwala R., &    Schäffer A.A. (2008) “Database indexing for production MegaBLAST    searches.” Bioinformatics 15:1757-1764. PubMed-   Camacho C., Coulouris G., Avagyan V., Ma N.. Papadopoulos J., Bealer    K., & Madden T.L. (2008) “BLAST+: architecture and applications.”    BMC Bioinformatics 10:421. PubMed-   Boratyn GM, Schäffer AA, Agarwala R, Altschul SF, Lipman DJ, &    Madden T.L. (2012) “Domain enhanced lookup time accelerated BLAST.”    Biol Direct. 2012 Apr 17;7:12. PubMed

1-18. (canceled)
 19. A method for minimizing the likelihood ofdevelopment of allergy in offspring of a female individual comprisingthe step of administering Prevotella to a female individual, therebyminimizing the likelihood of development of allergy in offspring of thefemale individual.
 20. The method of claim 19 wherein the femaleindividual is administered with Prevotella 1 to 3 months, preferably nomore than about 6 months, prior to her falling pregnant.
 21. The methodof claim 19 wherein the female individual is administered withPrevotella in the 1^(st), 2^(nd) or 3^(rd) trimester, or in alltrimesters.
 22. The method of claim 21 wherein the Prevotella isadministered for at least 2 months, preferably for at least 4 monthsbefore delivery.
 23. The method of claim 19 wherein the Prevotella thatis administered to the female individual comprises Prevotella copri. 24.The method of claim 19 wherein the female individual is administeredwith Prevotella to provide from 1×10⁶ to 1×10¹¹ colony forming units(cfu) of Prevotella per day to the female individual.
 25. The method ofclaim 19 wherein the Prevotella is administered once or twice daily, oronce every 2 or 3 days, or once weekly.
 26. The method of claim 19wherein the Prevotella is provided orally to the female individual inthe form of a capsule, tablet or like formulation adapted for oraladministration, or in the form of a food or beverage.
 27. A compositioncomprising: Prevotella copri; and a further ingredient that isbeneficial for a pregnant or lactating woman.
 28. The composition ofclaim 27 wherein the further ingredient is folate or vitamin D.
 29. Thecomposition of claim 27 wherein the further ingredient is iron.
 30. Thecomposition of claim 27, further comprising a carbohydrate.
 31. Thecomposition of claim 28, further comprising a carbohydrate.
 32. A methodfor determining the likelihood of a female individual forming offspringhaving allergic disease comprising: providing a control describing therelative abundance of Prevotella 16S rDNA in the stool of a mother whohas offspring who do not have allergic disease; obtaining a sample fromthe female individual for whom the likelihood of forming offspringhaving allergic disease is to be determined, thereby forming a testsample; comparing the test sample with the control to assess whether thetest sample has a relative abundance of Prevotella 16S rDNA as describedin the control; determining that the female individual has a lowlikelihood of forming offspring having allergic disease where the testsample has a relative abundance of Prevotella 16S rDNA as described inthe control determining that the female individual has a high likelihoodof forming offspring having allergic disease where the test sample has arelative abundance of Prevotella 16S rDNA that is not described in thecontrol.
 33. The method of claim 32 wherein where a female individualhas a lower relative abundance of a Prevotella 16S rDNA, preferably ofOTU00041 or SEQ ID No: 1 than the control, the female individual isassessed as having a higher likelihood of forming offspring havingallergic disease.
 34. The method of claim 33 wherein the test sample isa stool sample.